PIERIS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.16 USD | +0.18% |
|
-0.71% | -23.35% |
| Apr. 19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
| Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Presentation Operator MessageOperator (Operator)Good morning and welcome to the Pieris Pharmac...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Companyâs clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
| 1st Jan change | Capi. | |
|---|---|---|
| -23.35% | 13.78M | |
| +2.97% | 108B | |
| +10.21% | 105B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B |
- Stock Market
- Equities
- PIRS Stock
- News Pieris Pharmaceuticals, Inc.
- Transcript : Pieris Pharmaceuticals, Inc. - Shareholder/Analyst Call